`
`Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test | GenomeWeb
`
`Personalis, AstraZeneca Extend Collaboration
`Around Residual Cancer Detection Test
`
`Mar 07, 2023 | staff reporter
`
`Save for later
`
`NEW YORK – Personalis said Tuesday that it is continuing a collaboration with AstraZeneca to explore the
`cancer sequencing firm's NeXT Personal molecular residual disease (MRD) test in clinical research and
`drug development.
`
`The two companies are evaluating the sensitivity and specificity of whole-genome-informed circulating
`tumor DNA testing that supports both residual disease detection and assessment of clinically relevant
`mutations that may be used to guide future therapy decision-making.
`
`According to Personalis, the intent is to provide MRD detection, on-treatment therapy resistance tracking,
`and better differentiation between responders and non-responders in the drugmaker's clinical trials, as well
`as to investigate novel underlying mechanisms that drive cancers.
`
`The company said one trial covered by the partnership, called CALLA, will investigate the role of ctDNA
`and HPV detection in locally advanced cervical cancer. Other specifics, including financial details, were not
`disclosed.
`
`"Personalis designed NeXT Personal to provide ultra-high sensitivity and specificity for MRD detection. Our
`whole-genome, tumor-informed approach improves ctDNA measurement even when the plasma tumor
`fraction is exceptionally low, which is the case in multiple cancers with low mutational burden," CEO
`Christopher Hall said in a statement.
`
`"We are pleased that AstraZeneca is prioritizing such sensitivity, with the aim of enabling earlier and more
`personalized interventions for patients," he added.
`
`Filed Under
`
`Cancer
`
`Liquid Biopsy
`
`drug development
`
`Minimal Residual Disease (MRD) Testing
`
`circulating tumor DNA
`
`Personalis
`
`AstraZeneca
`
`cervical cancer
`
`collaboration
`
`North America
`
`Privacy Policy. Terms & Conditions. Copyright © 2023 GenomeWeb, a business unit of Crain
`Communications. All Rights Reserved.
`
`https://www.genomeweb.com/cancer/personalis-astrazeneca-extend-collaboration-around-residual-cancer-detection-test
`
`1/1
`
`Personalis EX2154
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
